Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology reported Q2 fiscal 2026 revenue of $1.7 million from its LYMPHIR launch, with H1 revenue reaching $5.6 million and gross margins stabilizing at approximately 80%. The company posted a net loss of $21.2 million for the quarter, heavily impacted by a $19.7 million one-time charge for a CMO contract cancellation, and ended with $4.6 million in cash. To extend its runway to November 2026, Citius Oncology secured up to $36.5 million in combined debt and equity financing, while parent Citius Pharma raised $5 million in a registered direct offering.
Key figures
- Revenue
- 1667298
- Guidance
- Operations funded through November 2026
- Revenue Yoy
- N/A (no revenue in prior year)
- H1 revenue
- 5611409
- Net loss h1
- 29451925
- Net loss q2
- 21231140
- Gross margin
- 80%
- Ga expense q2
- 26391101
- Rd expense q2
- 1633518
- Gross profit q2
- 1338420
- Offering proceeds
- 5000000
- Payer coverage pct
- near 100%
- Cash and equivalents
- 4590174
- Debt equity financing
- 36500000
- Formulary accounts pct
- 83%
- Cmo cancellation charge
- 19700000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.